Viatris (VTRS) official guidance

Our 2026 R&D priorities are to secure eight regulatory approvals for six product candidates to progress our innovative portfolio, advance six Phase III development programs, and continue to drive our generic pipeline and established brands portfolio, which together accounts for more than 100 new product approvals expected globally in 2026.

Turning to emerging markets, we expect to grow 6% year-over-year.

Yeah. On your question about the durability, I mean, you heard from my remarks, we've increased our expectation from the beginning of the year of low single digits to now mid to high single digit growth in China.

Lastly, in Greater China, we expect to deliver 3% year-over-year growth, driven primarily by our cardiovascular products that are sensitive to proactive patient choice.

North America is expected to be flat year-over-year, as new product revenues, primarily from complex products and ongoing strength from existing products such as Brina, Estradiol TDS, and Xulane, are expected to offset certain competitive impacts, including the Isosulfan Blue LOE.

The Company currently anticipates the impact of product supply disruptions to be between $100 million and $150 million to total revenues in the second half of 2026.

Turning to phasing for the remainder of the year, total revenues, adjusted EBITDA and adjusted EPS are still expected to be weighted to the second half at approximately 52% of our full year outlook.

| Less: Capital Expenditures | $(350) - $(450) |

| Less: Capital Expenditures | $(350) - ($450) |

| Adjusted EBITDA (1) | $4,150 - $4,450 | $4,300 |

| Adjusted EBITDA (1) | $4,150 - $4,450 | $4,300 |

| Adjusted EPS (1) | $2.33 - $2.47 | $2.40 |

| Adjusted EPS (1) | $2.33 - $2.47 | $2.40 |

| Free Cash Flow (1) Excluding Transaction-related and Restructuring-related Costs | $1,950 - $2,350 | $2,150 |

| Free Cash Flow (1) Excluding Transaction-related and Restructuring-related Costs | $1,950 - $2,350 | $2,150 |

The Company generated approximately $71 million in new product revenues in the quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2026.

We are anticipating new product revenues of $450-550 million, which are expected to contribute to strong segment performance.

The Company expects to deliver $450 million to $550 million in new product revenues in 2026.

With respect to your second question around new product revenue and how that ties into 2026, we've talked about the $450 million-$550 million. Without getting into specifics, we will provide that next year.

With respect to the Estimated Ranges provided on February 26, 2026, and reaffirmed on May 7, 2026, U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.7 billion and $2.0 billion, with a midpoint of approximately $1.85 billion.

U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.7 billion and $2.0 billion, with a midpoint of approximately $1.85 billion.

| Total Revenues | $14,450 - $14,950 | $14,700 |

| Total Revenues | $14,450 - $14,950 | $14,700 |

| Add: Estimated Transaction-related and Restructuring-related Costs | ~$700 |

•Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026

We expect to be in a strong financial position in 2026, with over $2.5 billion of cash available for deployment.